Our analysis predicted SORL1 as a candidate driver in multiple study groups, including myelodysplastic neoplasm (precursor of AML), B-cell precursor ALL, and a study group comprising T-cell non-Hodgkin lymphoma and T-cell acute lymphoblastic leukemia. Here, SORL1 is linked to acute myeloid leukemia.